Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a pioneer in the discovery and development of CAR-T cell therapies, organized a call today to provide an update on Celyad’s clinical strategy. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer, delivered a brief presentation followed by a Q&A session.

Click here to listen to the conference call

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad

Celyad Announces Third Quarter 2017 Business Update

Next News

Celyad Announces Third Quarter 2017 Business Update